Checkpoint Therapeutics, Inc. (CKPT): Price and Financial Metrics

Checkpoint Therapeutics, Inc. (CKPT): $2.68

-0.13 (-4.63%)

POWR Rating

Component Grades














  • Sentiment is the dimension where CKPT ranks best; there it ranks ahead of 83.34% of US stocks.
  • The strongest trend for CKPT is in Growth, which has been heading down over the past 31 weeks.
  • CKPT's current lowest rank is in the Stability metric (where it is better than 6.97% of US stocks).

CKPT Stock Summary

  • The ratio of debt to operating expenses for Checkpoint Therapeutics Inc is higher than it is for about just 0.51% of US stocks.
  • With a price/sales ratio of 1,353.32, Checkpoint Therapeutics Inc has a higher such ratio than 99.21% of stocks in our set.
  • Revenue growth over the past 12 months for Checkpoint Therapeutics Inc comes in at -92.91%, a number that bests only 1.39% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to CKPT, based on their financial statements, market capitalization, and price volatility, are MRSN, GERN, SVRA, CRDF, and MKGI.
  • CKPT's SEC filings can be seen here. And to visit Checkpoint Therapeutics Inc's official web site, go to

CKPT Price Target

For more insight on analysts targets of CKPT, see our CKPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.80 Average Broker Recommendation 1.4 (Strong Buy)

CKPT Stock Price Chart Interactive Chart >

Price chart for CKPT

CKPT Price/Volume Stats

Current price $2.68 52-week high $5.38
Prev. close $2.81 52-week low $1.56
Day low $2.67 Volume 1,440,700
Day high $2.83 Avg. volume 1,439,874
50-day MA $2.72 Dividend yield N/A
200-day MA $2.88 Market Cap 212.21M

Checkpoint Therapeutics, Inc. (CKPT) Company Bio

Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

CKPT Latest News Stream

Event/Time News Detail
Loading, please wait...

CKPT Latest Social Stream

Loading social stream, please wait...

View Full CKPT Social Stream

Latest CKPT News From Around the Web

Below are the latest news stories about Checkpoint Therapeutics Inc that investors may wish to consider to help them evaluate CKPT as an investment opportunity.

Why Checkpoint Therapeutics Skyrocketed Today

One very big stock market winner on Wednesday was Checkpoint Therapeutics (NASDAQ: CKPT). B. Riley Securities prognosticator Justin Walsh is bullish on Checkpoint. Walsh is so hot on Checkpoint's prospects, he's initiating his coverage with a buy rating and an $18 per-share price target -- which was nearly seven times Tuesday's closing stock price.

Yahoo | June 9, 2021

5 Top Stock Gainers for Wednesday: SPI Energy, Checkpoint Therapeutics

SPI Energy, Checkpoint Therapeutics, Aethlon Medical, Clovis Oncology and World Wrestling Entertainment are five top gainers for Wednesday.

Yahoo | June 9, 2021

Checkpoint Therapeutics Soars on B. Riley Buy Rating, $18 Price Target

B. Riley analyst Justin Walsh began coverage of Checkpoint, a cancer biotech company, with a buy rating and an $18 price target.

Yahoo | June 9, 2021

Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Rare Disease Therapeutics

The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Fortress Biotech (NASDAQ: FBIO) creates partner companies to manage and optimize cancer immunotherapy and other disease treatment development programs. Its broad portfolio of therapeutic categories includes oncology, rare disorder

Yahoo | June 3, 2021

Colonial Pipeline Cyberattack Puts All Eyes on FireEye

The cyberattack on the Colonial Pipeline is a good reason to take a renewed look at FEYE stock and other enterprise security stocks.

Joanna Makris on InvestorPlace | May 12, 2021

Read More 'CKPT' Stories Here

CKPT Price Returns

1-mo 1.13%
3-mo -23.43%
6-mo -0.37%
1-year 24.07%
3-year -4.29%
5-year N/A
YTD 1.13%
2020 54.07%
2019 -5.49%
2018 -53.09%
2017 N/A
2016 N/A

Continue Researching CKPT

Here are a few links from around the web to help you further your research on Checkpoint Therapeutics Inc's stock as an investment opportunity:

Checkpoint Therapeutics Inc (CKPT) Stock Price | Nasdaq
Checkpoint Therapeutics Inc (CKPT) Stock Quote, History and News - Yahoo Finance
Checkpoint Therapeutics Inc (CKPT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.867 seconds.